Goda Katalin, Bacsó Zsolt, Szabó Gábor
Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Curr Cancer Drug Targets. 2009 May;9(3):281-97. doi: 10.2174/156800909788166493.
P-glycoprotein (Pgp), coded for by the mdr1 gene, is one of the ABC transporters held responsible for the phenomenon of multidrug resistance (mdr), which is reflected by a rapidly escalating failure of chemotherapy with different classes of cytotoxic agents: anthracyclins, vinca alkaloids, taxanes, epipodophylotoxins. Although overcoming resistance conveyed by Pgp alone may not be sufficient for reaching effective treatment, the abundance of observations available for this paradigmatic multidrug transporter at both in vitro and in vivo setting is a tempting ground for an updated assessment of the main currents of mdr research. In this review we attempt to help keep track of the features of Pgp-mediated drug transport that serve as the major starting points for ongoing efforts of mdr reversal. We will analyze the slowly narrowing gaps that prevail between our ever increasing understanding at the protein, cell and organism level, focusing on the molecular interactions involving Pgp.
由mdr1基因编码的P-糖蛋白(Pgp)是ABC转运蛋白之一,它与多药耐药(mdr)现象有关,这一现象表现为使用不同种类的细胞毒性药物(蒽环类抗生素、长春花生物碱、紫杉烷类、表鬼臼毒素)进行化疗时迅速出现疗效下降。尽管仅克服Pgp介导的耐药性可能不足以实现有效治疗,但在体外和体内环境中针对这种典型多药转运蛋白已有大量观察结果,这为更新评估mdr研究的主要趋势提供了诱人的依据。在本综述中,我们试图梳理Pgp介导的药物转运的特征,这些特征是当前mdr逆转研究的主要出发点。我们将分析在蛋白质、细胞和生物体水平上,随着认识不断增加而逐渐缩小的差距,重点关注涉及Pgp的分子相互作用。